CinCor Pharma, Inc., (CINC): Price and Financial Metrics


CinCor Pharma, Inc., (CINC): $28.89

-0.04 (-0.14%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CINC to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CINC Stock Price Chart Interactive Chart >

Price chart for CINC

CINC Price/Volume Stats

Current price $28.89 52-week high $43.15
Prev. close $28.93 52-week low $10.53
Day low $28.75 Volume 361,800
Day high $29.16 Avg. volume 801,567
50-day MA $19.05 Dividend yield N/A
200-day MA $24.21 Market Cap 1.26B

CinCor Pharma, Inc., (CINC) Company Bio


CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for cardiovascular diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension and primary aldosteronism, as well as in Phase I clinical trial to treat chronic kidney diseases. CinCor Pharma, Inc. has a license agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.


CINC Latest News Stream


Event/Time News Detail
Loading, please wait...

CINC Latest Social Stream


Loading social stream, please wait...

View Full CINC Social Stream

Latest CINC News From Around the Web

Below are the latest news stories about CINCOR PHARMA INC that investors may wish to consider to help them evaluate CINC as an investment opportunity.

CinCor Pharma Inc. (CINC): Is It Worth A Small Bite At $28.95?

CinCor Pharma Inc. (NASDAQ:CINC) price on Friday, January 13, fall -0.41% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $28.95. A look at the stock’s price movement, the close in the last trading session was $29.07, moving within a range at $28.765 and $29.05. Turning to its … CinCor Pharma Inc. (CINC): Is It Worth A Small Bite At $28.95? Read More »

Stocks Register | January 14, 2023

Why These Two Biotech Stocks Blasted Higher This Week

Two somewhat under-the-radar biotech companies saw their share prices soar this week after agreeing to be acquired. CinCor Pharma (NASDAQ: CINC) is being bought out by deep-pocketed pharmaceutical company AstraZeneca, while Albireo Pharma (NASDAQ: ALBO) is set to be owned by France-based peer Ipsen. Both of these deals are very lucrative, to the point where CinCor's stock rocketed 146% over the course of the week, and Albireo shot 92% skyward, according to data compiled by S&P Global Market Intelligence.

Yahoo | January 13, 2023

Do investors need to be concerned about CinCor Pharma Inc. (CINC)?

The share price of CinCor Pharma Inc. (NASDAQ:CINC) rose to $28.80 per share on Tuesday from $28.74. While CinCor Pharma Inc. has overperformed by 0.21%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CINC rose by 80.00%, with highs and lows ranging from $43.15 to $10.53, […]

US Post News | January 11, 2023

AstraZeneca Is Acquiring CinCor Pharma: Market Values Interesting CVR At $3.21

AstraZeneca is acquiring Cincor Pharma for $26 per share and an interesting CVR. Learn more about the acquisition and my recommendation.

Seeking Alpha | January 11, 2023

Biotech Stock Roundup: REGN Down on Eylea Data, CINC Surges on AZN Offer & More

Updates from Regeneron (REGN) and CinCor Pharma (CINC) are the key highlights from the biotech sector during the past week.

Yahoo | January 11, 2023

Read More 'CINC' Stories Here

CINC Price Returns

1-mo 145.87%
3-mo -3.92%
6-mo 23.20%
1-year 53.92%
3-year N/A
5-year N/A
YTD 135.07%
2022 N/A
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6021 seconds.